Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNP520 · 1 trial · 1 indication
Safety monitoring was conducted throughout the study.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks. |
| CNP520 2 mg | EXPERIMENTAL | CNP520 2 mg was taken qd orally for 13 weeks. |
| CNP520 10 mg | EXPERIMENTAL | CNP520 10 mg was taken qd orally for 13 weeks. |
| CNP520 35 mg | EXPERIMENTAL | CNP520 35 mg was taken qd orally for 13 weeks. |
| CNP520 85 mg | EXPERIMENTAL | CNP520 85 mg was taken qd orally for 13 weeks. |
| Name | Type | Description |
|---|---|---|
| CNP520 | DRUG | - |
| Placebo | DRUG | Matching placebo to CNP520 was supplied in capsules. |
Key Inclusion Criteria: * Healthy status * Body weight: ≥45kg * BMI: 18-34 kg/m2 Key Exclusion Criteria: * History or presence of any clinically significant disease of any major system organ class. * Heavy smoker status * History /presence of clinically significant neurological or psychiatric dis...
Top 20 of 24 competitors
CNP520 is an investigational small molecule being studied for Alzheimer's disease. It is in Phase 2 clinical development and is intended for use in adults aged 60 years and older. The drug is being evaluated for its safety and tolerability in this population.
CNP520 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's potential in Alzheimer's disease.
CNP520 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for safety and tolerability in patients with Alzheimer's disease.
CNP520 has one completed Phase 2 clinical trial registered under NCT02576639. This was a dose-ranging safety and tolerability study in subjects aged 60 years and older, conducted in the United States, Belgium, Germany, Netherlands, and United Kingdom. The trial enrolled 124 participants.
CNP520 is a distinct investigational compound developed by Novartis AG. No alternative names for CNP520 have been reported in clinical trial registrations. It is being studied specifically for its potential role in Alzheimer's disease.